Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus and NY-ESO-1 Vaccine in Ovarian Cancer
NCT02833506Phase 1Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2017
- Primary completion
- Aug 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nab-sirolimus in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 cohorts), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Incidence of adverse events defined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 up to 30 days. Planned start Dec 2017; status: withdrawn.
02
Drugs
nab-sirolimus
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02833506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833506.